Silja Chouquet examines the Twitter noise at pharma meetings and offers pointers to keep KOLs engaged while avoiding the attention of worthless click-farm accounts.
In its bid to satisfy investors with returns on paid advertising, Twitter is damaging genuine engagement, while pharma's buying power is quoshing the opportunity for balanced conversations, say
Boehringer Ingelheim says it may have found the first therapy for diabetic macular ischaemia (DMI), a common and irreversible complication of the eye in people with diabet
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.